Registration Dossier
Registration Dossier
Data platform availability banner - registered substances factsheets
Please be aware that this old REACH registration data factsheet is no longer maintained; it remains frozen as of 19th May 2023.
The new ECHA CHEM database has been released by ECHA, and it now contains all REACH registration data. There are more details on the transition of ECHA's published data to ECHA CHEM here.
Diss Factsheets
Use of this information is subject to copyright laws and may require the permission of the owner of the information, as described in the ECHA Legal Notice.
EC number: 259-653-7 | CAS number: 55466-76-7
- Life Cycle description
- Uses advised against
- Endpoint summary
- Appearance / physical state / colour
- Melting point / freezing point
- Boiling point
- Density
- Particle size distribution (Granulometry)
- Vapour pressure
- Partition coefficient
- Water solubility
- Solubility in organic solvents / fat solubility
- Surface tension
- Flash point
- Auto flammability
- Flammability
- Explosiveness
- Oxidising properties
- Oxidation reduction potential
- Stability in organic solvents and identity of relevant degradation products
- Storage stability and reactivity towards container material
- Stability: thermal, sunlight, metals
- pH
- Dissociation constant
- Viscosity
- Additional physico-chemical information
- Additional physico-chemical properties of nanomaterials
- Nanomaterial agglomeration / aggregation
- Nanomaterial crystalline phase
- Nanomaterial crystallite and grain size
- Nanomaterial aspect ratio / shape
- Nanomaterial specific surface area
- Nanomaterial Zeta potential
- Nanomaterial surface chemistry
- Nanomaterial dustiness
- Nanomaterial porosity
- Nanomaterial pour density
- Nanomaterial photocatalytic activity
- Nanomaterial radical formation potential
- Nanomaterial catalytic activity
- Endpoint summary
- Stability
- Biodegradation
- Bioaccumulation
- Transport and distribution
- Environmental data
- Additional information on environmental fate and behaviour
- Ecotoxicological Summary
- Aquatic toxicity
- Endpoint summary
- Short-term toxicity to fish
- Long-term toxicity to fish
- Short-term toxicity to aquatic invertebrates
- Long-term toxicity to aquatic invertebrates
- Toxicity to aquatic algae and cyanobacteria
- Toxicity to aquatic plants other than algae
- Toxicity to microorganisms
- Endocrine disrupter testing in aquatic vertebrates – in vivo
- Toxicity to other aquatic organisms
- Sediment toxicity
- Terrestrial toxicity
- Biological effects monitoring
- Biotransformation and kinetics
- Additional ecotoxological information
- Toxicological Summary
- Toxicokinetics, metabolism and distribution
- Acute Toxicity
- Irritation / corrosion
- Sensitisation
- Repeated dose toxicity
- Genetic toxicity
- Carcinogenicity
- Toxicity to reproduction
- Specific investigations
- Exposure related observations in humans
- Toxic effects on livestock and pets
- Additional toxicological data
Endpoint summary
Administrative data
Description of key information
In a 4-week repeated dose toxicity study, to GLP, ruthenium acetate was administered by gavage to CD rats at 15, 150 or 1000 mg/kg bw/day. Effects at 1000 mg/kg bw/day exceeded the maximum tolerated dose and the study was terminated prematurely at week 3. The lower doses were generally well tolerated with findings restricted to minor variations in clinical pathology parameters and effects on the spleen. Although considered of low-severity, the effects on the spleen (enlargement in males and histopathological change) increased in incidence affecting one, to "several", to the "majority", of animals in the low-, mid- and high-dose groups, respectively. The low dose of 15 mg/kg bw/day is therefore considered the most appropriate to assign as the study NOAEL.
Key value for chemical safety assessment
Repeated dose toxicity: via oral route - systemic effects
Link to relevant study records
- Endpoint:
- short-term repeated dose toxicity: oral
- Type of information:
- experimental study
- Adequacy of study:
- supporting study
- Study period:
- "during 2004"
- Reliability:
- 2 (reliable with restrictions)
- Rationale for reliability incl. deficiencies:
- comparable to guideline study with acceptable restrictions
- Remarks:
- Full study report not available. The information provided is limited (particularly with regards to test material identity and methodology) to a summary (TSCA submission) of the draft study report and a subsequent expert apprasial
- Qualifier:
- equivalent or similar to guideline
- Guideline:
- OECD Guideline 407 (Repeated Dose 28-Day Oral Toxicity Study in Rodents)
- Version / remarks:
- The study design was based on the 1995 version. It included a Functional Observation Battery segment. No satellite (recovery) groups were incorporated.
- Deviations:
- yes
- Remarks:
- The dose level intervals exceeded the two- to four-fold steps considered optimal in study design, but did not exceed the typically applied maximum of ten-fold intervals.
- GLP compliance:
- yes
- Limit test:
- no
- Specific details on test material used for the study:
- SOURCE OF TEST MATERIAL
- Source and lot/batch No.of test material: not specified
- Expiration date of the lot/batch: not specified
- Purity test date: not specified
STABILITY AND STORAGE CONDITIONS OF TEST MATERIAL
- Storage condition of test material: not specified
- Stability under test conditions: not specified
- Solubility and stability of the test substance in the solvent/vehicle: not specified
- Reactivity of the test substance with the solvent/vehicle of the cell culture medium: not specified
TREATMENT OF TEST MATERIAL PRIOR TO TESTING
- Treatment of test material prior to testing: not specified
- Preliminary purification step (if any): not specified
- Final dilution of a dissolved solid, stock liquid or gel: not specified
- Final preparation of a solid: not specified
FORM AS APPLIED IN THE TEST (if different from that of starting material) not specified - Species:
- rat
- Strain:
- other: Crl:CD(SD) IGS BR
- Sex:
- male/female
- Details on test animals or test system and environmental conditions:
- TEST ANIMALS
- Source: Not specified.
- Age at study initiation: Not specified.
- Weight at study initiation: Not specified.
- Fasting period before study: Not specified.
- Housing: Not specified.
- Diet (e.g. ad libitum): Not specified.
- Water (e.g. ad libitum): Not specified.
- Acclimation period: Not specified.
ENVIRONMENTAL CONDITIONS
- Temperature (°C): Not specified.
- Humidity (%): Not specified.
- Air changes (per hr): Not specified.
- Photoperiod (hrs dark / hrs light): Not specified.
IN-LIFE DATES: From: To: Not specified. - Route of administration:
- oral: gavage
- Details on route of administration:
- Not specified.
- Vehicle:
- water
- Details on oral exposure:
- PREPARATION OF DOSING SOLUTIONS:
VEHICLE
- Concentration in vehicle: Not specified.
- Amount of vehicle (if gavage): Not specified.
- Lot/batch no. (if required): Not specified.
- Purity: Not specified.
"Solubility was apparently complete at the concentrations used for the dosing formulations" and "Analysed concentraitons versus nominals were within acceptable limits". - Analytical verification of doses or concentrations:
- yes
- Details on analytical verification of doses or concentrations:
- Analysed concentrations versus nominals were within acceptable limits.
- Duration of treatment / exposure:
- Male and female rats were treated for up to 4 weeks. The group of animals receiving 1000 mg/kg bw/day (the highest tested dose) were treated for only 3 weeks, as this dose level "exceeded the maximum tolerated dose."
- Frequency of treatment:
- Not specified (presumably daily administration).
- Dose / conc.:
- 15 mg/kg bw/day (nominal)
- Dose / conc.:
- 150 mg/kg bw/day (nominal)
- Dose / conc.:
- 1 000 mg/kg bw/day (nominal)
- Remarks:
- Dose level exceeded the maximum tolerated dose - group prematurely terminated (at week 3)
- No. of animals per sex per dose:
- 5 animals/sex/group, 3 groups, plus a "similarly constituted control group"
- Control animals:
- yes, concurrent vehicle
- Details on study design:
- - Dose selection rationale: Not specified. The dose level intervals exceeded the two- to four-fold steps considered optimal in study design, but did not exceed the typically applied maximum of ten-fold intervals.
- Observations and examinations performed and frequency:
- Limited details of this guideline study provided in available summary and apprasial. According to the former, "During the study, clinical condition, detailed physical and arena observations, sensory reactivity, grip strength, motor activity, bodyweight, food consumption, water consumption, haematology, blood chemistry, organ weight, macropathology and histopathology investigations were undertaken".
- Sacrifice and pathology:
- GROSS PATHOLOGY: Yes
HISTOPATHOLOGY: Yes - Other examinations:
- Included a Functional Observation Battery (FOB) segment.
- Statistics:
- Not specified.
- Clinical signs:
- effects observed, treatment-related
- Description (incidence and severity):
- At 1000 mg/kg bw/day (the highest tested dose), signs observed at detailed physical examination showed a general deterioration in clinical condition with observations such as thin build, respiratory problems, a dark discharge from the anus and dark staining on the tails. Also following anaesthesia for blood sampling the recovery times for these animals was noted to be longer than expected. Cage tray observations revealed green staining and dark faeces. Signs observed in association with dosing were: resistance to insertion of the catheter, salivation and noisy respiration. High dose group prematurely terminated at week 3.
At the low- and mid-dose groups (15 and 150 mg/kg bw/day respectively) no clinical signs were observed except darkened faeces. - Mortality:
- mortality observed, treatment-related
- Description (incidence):
- At 1000 mg/kg bw/day, 1 male and 2 females were killed in extremis.
No other deaths occurred. - Body weight and weight changes:
- effects observed, treatment-related
- Description (incidence and severity):
- At 1000 mg/kg bw/day, rats showed slightly low bodyweight gain during the first 2 weeks of treatment, with either bodyweight loss or stasis during the third week of treatment.
Bodyweight gain was unaffected at the low- and mid-dose levels. - Food consumption and compound intake (if feeding study):
- effects observed, treatment-related
- Description (incidence and severity):
- At 1000 mg/kg bw/day, "food consumption was low".
Food consumption was unaffected at the low- and mid-dose levels. - Food efficiency:
- effects observed, treatment-related
- Description (incidence and severity):
- At 1000 mg/kg bw/day, the food conversion efficiency was low during the first 2 weeks of treatment and was subsequently incalculable during the third week of treatment.
Food efficiency was unaffected at the low- and mid-dose levels. - Water consumption and compound intake (if drinking water study):
- effects observed, treatment-related
- Description (incidence and severity):
- At the highest tested dose, water consumption was elevated during the third week of treatment.
Water consumption was unaffected at the low- and mid-dose levels. - Ophthalmological findings:
- not specified
- Haematological findings:
- effects observed, treatment-related
- Description (incidence and severity):
- At 1000 mg/kg bw/day, white blood cell counts were "unselectively high" and slight/moderate hyperchromasia was apparent. Platelet counts were high, with males showing a decrease in the activated partial thromboplastin clotting time.
At 15 and 150 mg/kg bw/day, late stage elevations in white blood cell counts (including neutrophils) were observed, though these effects were not statistically significant.
"Group mean total white blood cell, neutrophil and lymphocyte counts showed elevations for females in all treated groups in a dose-related manner (although not achieving statistical significance). A similar, though less clear trend, was evident in respect of mean total white blood cell count and neutrophils for males [of the mid- and high-dose groups]." - Clinical biochemistry findings:
- effects observed, treatment-related
- Description (incidence and severity):
- Males receiving 1000 mg/kg bw/day showed high alanine amino-transferase activity and potassium levels. Females of this dose group showed high alanine-amino transferase activity, aspartate amino transferase activity and urea levels.
Males receiving 15 or 150 mg/kg bw/day had low albumin levels, with males at 150 mg/kg bw/day showing low total protein levels. Also, aspartate amino-transferase levels were slightly elevated for females at 15 or 150 mg/kg bw/day. - Urinalysis findings:
- not specified
- Behaviour (functional findings):
- not specified
- Immunological findings:
- not specified
- Organ weight findings including organ / body weight ratios:
- effects observed, treatment-related
- Description (incidence and severity):
- After 3 weeks of treatment, relative adrenal and spleen weights were high for both sexes, and males showed low thymus weights at the highest tested dose.
Absolute and relative spleen weights in males that received 15 or 150 mg/kg bw/day were high. Females receiving 150 mg/kg bw/day showed low relative heart weights. - Gross pathological findings:
- effects observed, treatment-related
- Description (incidence and severity):
- At 1000 mg/kg bw/day, the majority of macroscopic observations were confined to the gastro-intestinal tract with abnormal content, distension and thickening. Dark areas were observed primarily on the stomach wall and the limiting ridge was also thickened.
At 150 mg/kg bw/day, the "majority of females" showed abnormal gastrointestinal content at macroscopic examination.
No treatment-related effects were seen in the low-dose group. - Neuropathological findings:
- effects observed, treatment-related
- Description (incidence and severity):
- Degenerative peripheral and central nervous system lesions were detected at the top dose, generally described as "minimal" with the exception of two gradings of "slight" in relation to spinal cord lesions. In the sciatic nerve, degernate fibres were noted for all high-dose animals, and there was an increase in the incidence/severity of degernate fibres in the cervical, thoracic and lumbar section of the spinal cord.
- Histopathological findings: non-neoplastic:
- effects observed, treatment-related
- Description (incidence and severity):
- At 1000 mg/kg bw/day: In the spleen, myeloid hyperplasia (graded "slight" or "minimal") in the red pulp was evident in "the majority of animals", which may suggest extramedullary hematopoiesis as a secondary response to inflammatory changes elsewhere. Examination of the stomach showed ulceration, focal epithelial hyperplasia, subepithelial oedema, and inflammatory cell infiltrate in the nonglandular region, with epithelial necrosis, epithelial hyperplasia, hyperkeratosis and subepithelial oedema at the limiting ridge. Focal erosions, or necrosis, of fundic and/or antral mucosa, mucosal haemorrhage, submucosal oedema, and inflammatory cell infiltrate, were noted in the glandular region of the stomach. Examination of the intestines, showed focal mucosal necrosis, mucosal haemorrhage, and submucosal inflammatory cell infiltrate.
Microscopic examination of the spleen revealed myeloid hyperplasia in the red pulp for 1 male that received 15 mg/kg bw/day, and "a few animals" at 150 mg/kg bw/day. - Histopathological findings: neoplastic:
- not examined
- Other effects:
- not specified
- Key result
- Dose descriptor:
- NOAEL
- Effect level:
- 15 mg/kg bw/day (nominal)
- Based on:
- test mat.
- Sex:
- male/female
- Basis for effect level:
- other: No significant, treatment-related effects observed at this dose-level.
- Dose descriptor:
- LOAEL
- Effect level:
- 150 mg/kg bw/day (nominal)
- Based on:
- test mat.
- Sex:
- male/female
- Basis for effect level:
- histopathology: non-neoplastic
- organ weights and organ / body weight ratios
- Key result
- Critical effects observed:
- yes
- Lowest effective dose / conc.:
- 150 mg/kg bw/day (nominal)
- System:
- haematopoietic
- Organ:
- leucocyte development
- spleen
- Treatment related:
- yes
- Dose response relationship:
- yes
- Relevant for humans:
- yes
- Conclusions:
- In a 4-week repeated dose toxicitystudy, to GLP, ruthenium acetate was administered by gavage to CD rats at 15, 150 or 1000 mg/kg bw/day. Effects at 1000 mg/kg bw/day exceeded the maximum tolerated dose and the study was terminated prematurely at week 3. The lower doses were generally well tolerated with findings restricted to minor variations in clinical pathology parameters and effects on the spleen. Although considered of low-severity, the effects on the spleen (enlargement in males and histopathological change) increased in incidence affecting one, to "several", to the "majority", of animals in the low-, mid- and high-dose groups, respectively. The low dose of 15 mg/kg bw/day is therefore considered the most appropriate to assign as the study NOAEL.
- Executive summary:
In a repeated dose toxicity study, generally conducted in conformance with OECD Test Guideline 407 and performed to GLP, CD rats (5/sex/group) were administered ruthenium acetate (CAS RN 55466-76-7) by oral gavage for 4 weeks at dose levels of 15, 150 or 1000 mg/kg bw/day. A control group received vehicle only (water). During the study, clinical condition, detailed physical and arena observations, sensory reactivity, grip strength, motor activity, bodyweight, food consumption, water consumption, haematology, blood chemistry, organ weight, macropathology and histopathology investigations were undertaken, and a Functional Observation Battery (FOB) segment was included.
Administration of 1000 mg/kg bw/day (the highest tesed dose) exceeded the maximum tolerated dose, resulting in mortality, significant clincal signs, effects on haematology and clincial chemistry (indicative of effects on the liver and kidney), and macroscopic and histopathological changes in the spleen, stomach and intestines, and spinal cord and sciatic nerve. The premature termination of the high dose group occurred after 3 weeks of treatment. Doses of 15 or 150 mg/kg bw/day (for 4 weeks) were generally well tolerated with findings restricted to minor variations in clinical pathology parameters and myeloid hyperplasia in the red pulp of the spleen. Although of low-severity, the effects on the spleen (enlargement in males and coincident histopathological change) increased in incidence affecting one, to "several", to the "majority", of animals in the low-, mid- and high-dose groups, respectively. As such, the low dose group (15 mg/kg bw/day) appears the most appropriate to assign as a robust and health-precautionary study NOAEL.
Reference
Endpoint conclusion
- Endpoint conclusion:
- adverse effect observed
- Dose descriptor:
- NOAEL
- 15 mg/kg bw/day
- Study duration:
- subacute
- Species:
- rat
- System:
- haematopoietic
- Organ:
- leucocyte development
- spleen
Repeated dose toxicity: inhalation - systemic effects
Endpoint conclusion
- Endpoint conclusion:
- no study available
Repeated dose toxicity: inhalation - local effects
Endpoint conclusion
- Endpoint conclusion:
- no study available
Repeated dose toxicity: dermal - systemic effects
Endpoint conclusion
- Endpoint conclusion:
- no study available
Repeated dose toxicity: dermal - local effects
Endpoint conclusion
- Endpoint conclusion:
- no study available
Additional information
Justification for classification or non-classification
Although the results from the 28-day gavage study in rats indicate a LOAEL of 150 mg/kg bw/day, it is not considered that “significant organ damage” was observed at this dose. As such, classification as STOT RE is not required based on the results of this oral rat 28-day study, according to EU CLP critieria.
Information on Registered Substances comes from registration dossiers which have been assigned a registration number. The assignment of a registration number does however not guarantee that the information in the dossier is correct or that the dossier is compliant with Regulation (EC) No 1907/2006 (the REACH Regulation). This information has not been reviewed or verified by the Agency or any other authority. The content is subject to change without prior notice.
Reproduction or further distribution of this information may be subject to copyright protection. Use of the information without obtaining the permission from the owner(s) of the respective information might violate the rights of the owner.